MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.

IF 6.9 1区医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2024-11-20 DOI:10.1038/s41541-024-01009-5

Marco Polo Peralta-Álvarez, Keya Downward, Andrew White, Hugo Redondo Azema, Laura Sibley, Charlotte Sarfas, Alexandra Morrison, Mike Dennis, Delia Diaz-Santana, Stephanie A Harris, Shuailin Li, Eugenia Puentes, Nacho Aguilo, Carlos Martin, Sally Sharpe, Helen McShane, Rachel Tanner

{"title":"MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.","authors":"Marco Polo Peralta-Álvarez, Keya Downward, Andrew White, Hugo Redondo Azema, Laura Sibley, Charlotte Sarfas, Alexandra Morrison, Mike Dennis, Delia Diaz-Santana, Stephanie A Harris, Shuailin Li, Eugenia Puentes, Nacho Aguilo, Carlos Martin, Sally Sharpe, Helen McShane, Rachel Tanner","doi":"10.1038/s41541-024-01009-5","DOIUrl":null,"url":null,"abstract":"<p><p>The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations. To better understand the immune mechanisms underlying the superior efficacy conferred by MTBVAC, we characterized M.tb-specific antibody responses in NHPs vaccinated with either BCG or MTBVAC. MTBVAC vaccination induced higher titers of IgG, IgM and IgA, and higher avidity IgG compared with BCG vaccination. IgG avidity correlated with protection following M.tb challenge in the same animals, validating the association previously reported between this measure and protection in the context of intravenous BCG vaccination, suggesting that IgG avidity may represent a relevant marker or correlate of protection from TB.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"230"},"PeriodicalIF":6.9000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-01009-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations. To better understand the immune mechanisms underlying the superior efficacy conferred by MTBVAC, we characterized M.tb-specific antibody responses in NHPs vaccinated with either BCG or MTBVAC. MTBVAC vaccination induced higher titers of IgG, IgM and IgA, and higher avidity IgG compared with BCG vaccination. IgG avidity correlated with protection following M.tb challenge in the same animals, validating the association previously reported between this measure and protection in the context of intravenous BCG vaccination, suggesting that IgG avidity may represent a relevant marker or correlate of protection from TB.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

与卡介苗相比，MTBVAC 能在非人灵长类动物中诱导出更高的抗体滴度和 IgG 效价。

目前唯一获得许可的结核病（TB）疫苗--卡介苗（BCG）--不足以控制疫情。MTBVAC 是结核分枝杆菌（M.tb）的减毒活株，是目前最先进的结核病候选疫苗之一。在包括非人灵长类动物（NHPs）在内的临床前模型中，它比卡介苗更有效，并已在人类人群中证明了其安全性和免疫原性。为了更好地了解 MTBVAC 带来卓越疗效的免疫机制，我们对接种卡介苗或 MTBVAC 的非人灵长类动物的 M.tb 特异性抗体反应进行了鉴定。与接种卡介苗相比，接种 MTBVAC 可诱导更高滴度的 IgG、IgM 和 IgA 以及更高的 IgG 阳性。在相同的动物中，IgG的热敏性与M.tb挑战后的保护相关，验证了之前报道的静脉注射卡介苗时该指标与保护之间的关联，表明IgG的热敏性可能是结核病保护的相关标记或相关因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.